WT1 and polymyalgia rheumatica: Thirty-seven SAEs were reported by 20 patients (Table 1); two were considered by the investigators to be related/possibly related to WT1-immunotherapeutic administration: grade 2 polymyalgia rheumatica (cohort A; also reported as potential immune-mediated disorder) and diarrhea (mentioned above).